Silvana Pannain, MD, is a skilled endocrinologist. She provides advanced endocrinology care for patients who have weight problems, endocrine disorders or obesity.
Dr. Pannain serves as director of Chicago Weight, a multidisciplinary weight loss program at the University of Chicago Medicine. She works closely with teams of specialists — including behavior therapists, dietitians, exercise therapists, bariatric surgeons, cardiologists, lipidologists, hypertension specialists and sleep specialists — to develop comprehensive weight management plans for adult patients. These multidisciplinary teams combine counseling and medical treatment options to help patients lose weight. The Chicago Weight program also teaches patients to maintain a healthy lifestyle by permanently changing diet, exercise and behaviors.
Dr. Pannain's clinical and research interests include obesity, metabolic syndrome and related health conditions, such as obstructive sleep apnea and diabetes. She investigates the metabolic and endocrine aspects of chronic partial sleep loss, which is generally considered a risk factor for obesity and insulin resistance.
Diagnostic innovation and models of care to improve fibrosis detection and risk stratification in steatotic liver disease.
Diagnostic innovation and models of care to improve fibrosis detection and risk stratification in steatotic liver disease. Lancet Reg Health Eur. 2026 Jun; 65:101722.
PMID: 42266906
Exploring metabolomic clues in diabetic retinopathy: a pilot study.
Exploring metabolomic clues in diabetic retinopathy: a pilot study. Acta Diabetol. 2026 Jun; 63(6):1137-1141.
PMID: 41843083
Awareness of metabolic dysfunction-associated steatotic liver disease (MASLD) among primary care providers in the four most populous U.S. cities.
Awareness of metabolic dysfunction-associated steatotic liver disease (MASLD) among primary care providers in the four most populous U.S. cities. Ann Hepatol. 2026 Mar 11; 31(2):102200.
PMID: 41825781
Best buys for metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis: a global Delphi study.
Best buys for metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis: a global Delphi study. Lancet Gastroenterol Hepatol. 2026 Mar; 11(3):232-242.
PMID: 41397405
Cost of Metabolic Dysfunction-Associated Steatotic Liver Disease Screening Among All People Living With Diabetes in Six Countries.
Cost of Metabolic Dysfunction-Associated Steatotic Liver Disease Screening Among All People Living With Diabetes in Six Countries. Liver Int. 2025 12; 45(12):e70390.
PMID: 41194401
Multidimensional sleep health in type 2 diabetes: The role of sleep variability in glycemic control.
Multidimensional sleep health in type 2 diabetes: The role of sleep variability in glycemic control. Sleep Med. 2025 12; 136:106861.
PMID: 41130141
GLP-1 RA Medication Associations With Hazardous Alcohol Drinking Reductions in Patients With Overweight or Obesity: A Prospective Observational Study.
GLP-1 RA Medication Associations With Hazardous Alcohol Drinking Reductions in Patients With Overweight or Obesity: A Prospective Observational Study. J Addict Med. 2026 May-Jun 01; 20(3):375-380.
PMID: 40792626
The People-First Liver Charter.
The People-First Liver Charter. Nat Med. 2025 Jul; 31(7):2109-2116.
PMID: 40473951
Awareness of metabolic dysfunction-associated steatotic liver disease (MASLD) in 4 major cities in the United States.
Awareness of metabolic dysfunction-associated steatotic liver disease (MASLD) in 4 major cities in the United States. Hepatol Commun. 2025 May 01; 9(5).
PMID: 40331869
The Role of GLP-1 Agonists in Mitigating Lorlatinib-Induced Metabolic Syndrome: Two Case Studies.
The Role of GLP-1 Agonists in Mitigating Lorlatinib-Induced Metabolic Syndrome: Two Case Studies. Clin Lung Cancer. 2025 Jul; 26(5):429-433.
PMID: 40157899